In a significant development, the United States has granted exemption to Indian pharmaceuticals from tariffs imposed by President Trump, acknowledging their vital contribution to global healthcare. This exemption underscores India’s status as a major supplier of cost-effective generic drugs. Both countries emphasize the strategic value of their trade ties, with the exemption presenting India with opportunities to boost its pharmaceutical industry.